Downregulation of PUMA underlies resistance to FGFR1 inhibitors in the stem cell leukemia/lymphoma syndrome

Resistance to molecular therapies frequently occur due to genetic changes affecting the targeted pathway. In myeloid and lymphoid leukemias/lymphomas resulting from constitutive activation of FGFR1 kinases, resistance has been shown to be due either to mutations in FGFR1 or deletions of PTEN. RNA-Se...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Yun, Cai, Baohuan, Chong, Yating, Zhang, Hualei, Kemp, Chesley-Anne, Lu, Sumin, Chang, Chang-Sheng, Ren, Mingqiang, Cowell, John K., Hu, Tianxiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7576156/
https://www.ncbi.nlm.nih.gov/pubmed/33082322
http://dx.doi.org/10.1038/s41419-020-03098-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7576156/
https://www.ncbi.nlm.nih.gov/pubmed/33082322
http://dx.doi.org/10.1038/s41419-020-03098-1

Ejemplares similares